Preliminary report on postmenopausal endometrial hyperplasia treatment with Danazol: histological and endocrinological aspects.

Jasonni Vm, V M Jasonni, S Naldi, La Marca L, L La Marca, Carlo Bulletti, C Bulletti, Patrizia Ciotti, P Ciotti, A Vignudelli, C Flamigni
Cancer detection and prevention · 1986 · vol. 9(3-4) , pp. 331–5 · PMID:3742508 · W2409212125
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Danazol treatment of postmenopausal endometrial hyperplasia caused regression of hyperplasia and suggested inhibition of peripheral sulfatase activity, thereby reducing active unconjugated estrogens.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The synthetic steroid Danazol is commonly used in the hormonal treatment of endometriosis; however, little is known about its effects on human endometrium. This study was performed to verify the efficacy of Danazol on the treatment of endometrial hyperplasia in postmenopausal patients. Ten patients with histologically proven endometrial hyperplasia were treated with Danazol at a dosage of 600 mg/day for 30 days. The E1S and E1 plasma levels were also determined before and at the end of therapy. In all patients the regression of endometrial hyperplasia was observed in the endometrial biopsy specimens obtained after the treatment. Furthermore, the increased E1S/E1 ratio as compared to the basal values suggests an impairment of the peripheral sulfatase activity. The inhibition of the conversion of E1S to active unconjugated estrogens appears to be one of the mechanisms by which Danazol may act on the endometrium.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometrial Hyperplasia Pregnadienes Danazol Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Hyperplasia Estrone Estrone Female Humans Menopause Middle Aged Pregnadienes

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:40.384591+00:00
License: CC0 · commercial use OK